Enveda raises $311M to push nature-derived AI drugs into clinical trials

Enveda has raised $311 million in a new funding round that values the AI biotech company at $2 billion, according to a TechCrunch report published on September 23.

The company's approach starts with nature rather than the lab bench. Instead of designing molecules from scratch, Enveda searches natural sources for promising drug leads and uses artificial intelligence to speed up screening, matching and validation. The bet is that nature has already generated a vast space of molecular structures, and that machine learning can help researchers find the few with genuine therapeutic value faster than conventional methods.

On the clinical side, Enveda is currently testing drugs in two areas. One treats skin conditions. The other addresses a problem with unusually large commercial stakes: helping patients keep weight off after they stop taking GLP-1 medications.

That second program matters because weight regain after stopping GLP-1 drugs is one of the most visible limitations of the current generation of obesity treatments. A therapy that maintains results after patients discontinue a GLP-1 would create a distinct and potentially very large treatment segment rather than competing head-on with existing injections.

The $2 billion valuation suggests investors are still willing to pay a premium for the AI-plus-biology story, but the capital appears to be concentrating in companies that already have candidates in the clinic rather than in purely computational platforms. Enveda's two programs are both in testing, which means the company has moved past the concept stage and now faces the expensive parts of drug development: clinical data, regulators and manufacturing scale-up.

What to watch next is the pace of clinical readouts and how the new capital is deployed across the pipeline. For drug discovery companies that market themselves on AI, the real test is not how sophisticated the models are but whether candidates reach approval.